POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH trial in mCRPC at the 2022 SNMMI Mid-Winter & ACNM Annual Meeting
Dosimetry data demonstrated PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied...